Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Aims: Although it has been reported that angiotensin II receptor blocker inhibited the formation and accumulation of advanced glycation endproducts (AGEs) in vitro and in vivo, whether it can do so clinically is unknown. We therefore examined the effect of valsartan on markers of oxidation and glycation. Methods: We started 40 mg/day valsartan treatment in 15 type 2 diabetic subjects with hypertension, and metabolic parameters, lipid peroxide, paraoxonase activity, platelet-activating factor acethylhydrolase activity, AGEs and urine 8-isoprostane were measured at baseline and after 3 and 6 months of treatment. Results: Even after valsartan treatment, the blood pressure level of the patients did not change during the study. However, AGEs and urine 8-isoprastane levels had decreased at 6 months (p < 0.05 and <0.01) as well as urine microalbumin level (p < 0.01), although other oxidative stress markers were unchanged. Conclusion: In this study, low-dose valsartan treatment decreased serum AGEs level, whereas blood pressure level was unchanged. The effect of valsartan on AGEs might be a blood pressure-independent effect in type 2 diabetic subjects.

Original languageEnglish
Pages (from-to)201-203
Number of pages3
JournalDiabetes Research and Clinical Practice
Volume74
Issue number2
DOIs
Publication statusPublished - 2006 Nov

Fingerprint

Valsartan
Angiotensin Receptor Antagonists
Blood Pressure
8-epi-prostaglandin F2alpha
Urine
Aryldialkylphosphatase
Lipid Peroxides
Platelet Activating Factor
Therapeutics
Oxidative Stress
Hypertension

Keywords

  • Advanced glycation endproducts
  • Angiotensin II receptor blocker
  • Oxidative stress marker
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{cb43400d18bd47749e3f8011aa87ad75,
title = "Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan",
abstract = "Aims: Although it has been reported that angiotensin II receptor blocker inhibited the formation and accumulation of advanced glycation endproducts (AGEs) in vitro and in vivo, whether it can do so clinically is unknown. We therefore examined the effect of valsartan on markers of oxidation and glycation. Methods: We started 40 mg/day valsartan treatment in 15 type 2 diabetic subjects with hypertension, and metabolic parameters, lipid peroxide, paraoxonase activity, platelet-activating factor acethylhydrolase activity, AGEs and urine 8-isoprostane were measured at baseline and after 3 and 6 months of treatment. Results: Even after valsartan treatment, the blood pressure level of the patients did not change during the study. However, AGEs and urine 8-isoprastane levels had decreased at 6 months (p < 0.05 and <0.01) as well as urine microalbumin level (p < 0.01), although other oxidative stress markers were unchanged. Conclusion: In this study, low-dose valsartan treatment decreased serum AGEs level, whereas blood pressure level was unchanged. The effect of valsartan on AGEs might be a blood pressure-independent effect in type 2 diabetic subjects.",
keywords = "Advanced glycation endproducts, Angiotensin II receptor blocker, Oxidative stress marker, Type 2 diabetes",
author = "Yoshifumi Saisho and Naoko Komiya and Hiroshi Hirose",
year = "2006",
month = "11",
doi = "10.1016/j.diabres.2006.04.015",
language = "English",
volume = "74",
pages = "201--203",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects

T2 - Blood pressure-independent effect of valsartan

AU - Saisho, Yoshifumi

AU - Komiya, Naoko

AU - Hirose, Hiroshi

PY - 2006/11

Y1 - 2006/11

N2 - Aims: Although it has been reported that angiotensin II receptor blocker inhibited the formation and accumulation of advanced glycation endproducts (AGEs) in vitro and in vivo, whether it can do so clinically is unknown. We therefore examined the effect of valsartan on markers of oxidation and glycation. Methods: We started 40 mg/day valsartan treatment in 15 type 2 diabetic subjects with hypertension, and metabolic parameters, lipid peroxide, paraoxonase activity, platelet-activating factor acethylhydrolase activity, AGEs and urine 8-isoprostane were measured at baseline and after 3 and 6 months of treatment. Results: Even after valsartan treatment, the blood pressure level of the patients did not change during the study. However, AGEs and urine 8-isoprastane levels had decreased at 6 months (p < 0.05 and <0.01) as well as urine microalbumin level (p < 0.01), although other oxidative stress markers were unchanged. Conclusion: In this study, low-dose valsartan treatment decreased serum AGEs level, whereas blood pressure level was unchanged. The effect of valsartan on AGEs might be a blood pressure-independent effect in type 2 diabetic subjects.

AB - Aims: Although it has been reported that angiotensin II receptor blocker inhibited the formation and accumulation of advanced glycation endproducts (AGEs) in vitro and in vivo, whether it can do so clinically is unknown. We therefore examined the effect of valsartan on markers of oxidation and glycation. Methods: We started 40 mg/day valsartan treatment in 15 type 2 diabetic subjects with hypertension, and metabolic parameters, lipid peroxide, paraoxonase activity, platelet-activating factor acethylhydrolase activity, AGEs and urine 8-isoprostane were measured at baseline and after 3 and 6 months of treatment. Results: Even after valsartan treatment, the blood pressure level of the patients did not change during the study. However, AGEs and urine 8-isoprastane levels had decreased at 6 months (p < 0.05 and <0.01) as well as urine microalbumin level (p < 0.01), although other oxidative stress markers were unchanged. Conclusion: In this study, low-dose valsartan treatment decreased serum AGEs level, whereas blood pressure level was unchanged. The effect of valsartan on AGEs might be a blood pressure-independent effect in type 2 diabetic subjects.

KW - Advanced glycation endproducts

KW - Angiotensin II receptor blocker

KW - Oxidative stress marker

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=33751071901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751071901&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2006.04.015

DO - 10.1016/j.diabres.2006.04.015

M3 - Article

C2 - 16737758

AN - SCOPUS:33751071901

VL - 74

SP - 201

EP - 203

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 2

ER -